Clinical Trials Logo

Clinical Trial Summary

In this study we aim to evaluate hemodynamic effects of IVF treatment, with the use of the non invasive NICaS bioimpendence monitor.

Our study's primary end point is to evaluate the hemodynamic profile with the use of NICaS whole body impedance cardiography that occur throughout the IVF cycle in patients undergoing controlled ovarian stimulation during IVF treatment.

Secondary endpoints include:

Women will be asked to grade their pain score and level of anxiety by the use of the visual analogue score elicited throughout the study observation points, in order to examine whether pain scores and anxiety levels correlate with the hemodynamic changes throughout an IVF treatment cycle.


Clinical Trial Description

This is a prospective, observational, single center study which will be conducted at the Rabin Medical Center (Beilinson Campus), Petach Tikva, Israel, a tertiary university hospital. Fifty healthy woman (≤45 years old) undergoing IVF treatment will be enrolled following filling out an informed consent form.

Study procedure:

Women will be recruited in the IVF department upon consulting with the fertility specialist. Following signed informed consent, patients' blood pressure will be measured using a non-invasive upper arm blood pressure. Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes.

Monitoring will be performed on:

1. 1-3rd day of the menstrual cycle prior to treatment with gonadotropins

2. On the day of ovulation triggering

3. On the day of ovum pickup prior to their entrance to the operating theater.

4. On the day of embryo transfer.

IVF Protocol:

The antagonist protocol consists of daily gonadotropin stimulation from day 3 or 4 of menstruation. In addition, once the leading follicle reached 13-14 mm, daily injections of Cetrotide 0.25 mg (Serono, Switzerland) or Orgalutran 0.25 mg (N.V. Organon, the Netherlands) are given and until the day of hCG (Ovitrelle, Serono, Switzerland) injection. Gonadotropin stimulation will consist of recombinant FSH (Gonal F, Serono, Postfach, Switzerland; or Puregon, N.V. Organon, Oss, The Netherlands), alone or in combination with urinary gonadotropins (Menopur, Ferring, Kiel, Germany). During treatment, the ovarian response will be monitored by serial vaginal ultrasound measurements of follicular growth and serum E2 level every 1-3 days, starting on the fourth or fifth day of stimulation, gonadotropin dosage will be adjusted accordingly. When at least 3 follicles reached at least 17 millimeters, hCG is injected and thirty six hours after hCG injection, follicles will be aspirated in the operating room.

Data Collection:

Recorded data will include:

- Cardiac Output and its derivate including: systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), stroke volume (SV), cardiac output (CO) and total peripheral resistance (TPR).

- Demographic and obstetric age, weight, height, current hemoglobin, comorbidities, regular medication and other obstetric data.

Data Handling Data collection for all participants in the study will be done anonymously. All hemodynamic data collected will be done by a trained member of the research team. All collected data will be coded and recorded on the eCRF NICaS monitor, and will be accessible only to a member of the research team.

Study duration:

The study duration for each participant will be throughout the IVF cycle of treatment approximately 6 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03713723
Study type Observational
Source Rabin Medical Center
Contact
Status Recruiting
Phase
Start date June 1, 2017
Completion date December 2020

See also
  Status Clinical Trial Phase
Completed NCT04213781 - Interest of Audiovisual Distraction in the Management of Anxiety and Pain During Oocyte Retrieval N/A
Completed NCT00608010 - Day 3 Embryo Cryopreservation: Metabolic and Viability Analysis N/A
Completed NCT03527823 - The Comparison of Granulosa Cell Apoptosis Rates With or Without Luteinizing Hormone Administration in Poor Responders.
Terminated NCT02990949 - The Impact of the Timing of Trigger on IVF Success N/A
Not yet recruiting NCT02971280 - Influence of Heavy Metals Exposure on in Vitro Fertilization (IVF) Outcome N/A
Completed NCT00920361 - Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)
Recruiting NCT06134609 - Does Sexual Intercourse Affect the Outcomes of Frozen-thawed Embryo Transfer? N/A
Completed NCT03238833 - Poor Ovarian Responders Undergoing IVF Using Luteal Ovarian Stimulation Versus Follicular Ovarian Stimulation N/A
Withdrawn NCT03062098 - Optimizing the Technique of Embryo Transfer in IVF Using Better Imaging Guidance N/A
Recruiting NCT06410417 - Ejaculation Abstinence Time and Assisted Reproductive Technology Outcomes N/A
Not yet recruiting NCT06385444 - IVF Failure and Pregnancy Loss on Couples' Psychological Stress
Recruiting NCT03700255 - Efficacy of a Simulator Based (PickUpSimTM) Residents' Training Program for Oocyte Retrievals N/A
Recruiting NCT04935658 - Oocyte Retrieval and Virtual Reality (REVPO) N/A
Completed NCT03733912 - Plasticizers and in Vitro Fertilization Outcomes
Not yet recruiting NCT06433518 - BEst Size for Ovulation Triggering in Poseidon 4 Patients (BEST 4 Study)
Completed NCT02323347 - Cut-Off Progesterone Values Deleterious for In Vitro Fertilization and Fresh Embryo Transfer N/A
Completed NCT00750451 - Low Molecular Weight Heparin in Recurrent Implantation Failure N/A
Recruiting NCT04124913 - Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles Phase 4
Recruiting NCT06177613 - Benefit of Early Intrauterine Transfer of "Blank" Culture Medium Prior to Transfer of a Thawed Embryo From 1st in Vitro Fertilization N/A
Completed NCT04755270 - Virtual Reality-Supported Hypnofertility N/A